ArticleDiscover oncology2025
Research progress and frontier trends in liver cancer immunotherapy in the post-COVID-19 era (2020-2024): a visualization analysis based on bibliometric methods.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe COVID-19 pandemic has transformed liver cancer research, making immunotherapy a key breakthrough for advanced cases. This study uses bibliometrics to reveal research hotspots and paradigm shifts of this field from 2020 to 2024.
methodsThe data were retrieved from the Web of Science Core Collection (2020 to 2024). Data quality was ensured through two rounds of independent data cleaning, achieving a Kappa coefficient of 0.89. A comprehensive bibliometric analysis was conducted on the literature related to liver cancer immunotherapy, utilizing tools such as Biblioshiny, VOSviewer, Scimago Graphica, CiteSpace, and Microsoft Office Excel (2022 version).
resultsFrom 2020 to 2024, China and the US led global liver cancer immunotherapy research, forming a collaboration network with Canada. Sun Yat-sen University is a key hub with over 600 publications and an annual growth rate of 18.5%, closely collaborating with Huazhong University of Science and Technology and Zhejiang University (correlation index 0.92). The journal impact is dominated by Frontiers in Immunology and Frontiers in Oncology, which form a dual-core citation network, with the top 1% journals contributing 35.7% of publications. Frontiers in Immunology has the highest h-index (35) and fastest growth rate. The co-citation network includes three major clusters: immune mechanisms (led by Nature), clinical trials (Clinical Cancer Research), and liver cancer pathology (Hepatology). Research themes evolve in four directions: prognostic models, tumor microenvironment, hepatocellular carcinoma mechanisms, and cancer immunotherapy. Hotspots include "cancer", "immunotherapy", and "hepatocellular carcinoma", with rising trends in "tumor microenvironment" and "combination therapy" after 2021.
conclusionThe COVID-19 pandemic has spurred multidisciplinary integration and the use of real-world evidence in research. Emerging themes like Sino-American collaboration, knowledge diffusion in core journals, and tumor microenvironment are shaping liver cancer immunotherapy research in the post-pandemic era. This study offers strategic insights for optimizing resources and advancing clinical-basic translational research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.